MK-7684A con o sin otros tratamientos oncológicos en participantes con tumores sólidos seleccionados
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors.